Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04585139 · ClinicalTrials.gov registry record · NA

Assessing Non-adjunctive CGM Safety at Home and in New Markets

A NA study of Diabetes Mellitus, sponsored by DexCom.

Completed
Registry status
NA
Development phase
85
Enrollment target
1
Study location

NCT04585139 is a NA study of Diabetes Mellitus that has completed, run by DexCom. The registered enrollment target is 85 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04585139, a NA study of Diabetes Mellitus, has completed, sponsored by DexCom.

COMPLETED
Registry status
NA
Development phase
85 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to examine whether non-adjunctive (without having to double check using another method) use of Continuous Glucose Monitoring improves A1c in adults or children with diabetes managed by intensive insulin therapy.

Conditions Studied

Interventions

  • DEVICE Phase 1- Introduction to Dexcom G6 CGM

Study Locations (1)

Nevada

  • Las Vegas Endocrinology - Henderson

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2020-10-06
Est. Completion 2022-02-07
Phase NA

Sponsor

DexCom

26 total trials

What the Registry Record Tells You About NCT04585139

The ClinicalTrials.gov registry entry for NCT04585139 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (95% lower). The listed sponsor is DexCom, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Phase 1- Introduction to Dexcom G6 CGM is the first listed.

NCT04585139 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT04585139 about?

NCT04585139 is a clinical study titled "Assessing Non-adjunctive CGM Safety at Home and in New Markets". The purpose of the study is to examine whether non-adjunctive (without having to double check using another method) use of Continuous Glucose Monitoring improves A1c in adults or children with diabetes managed by intensive insulin therapy.

What is the current status of trial NCT04585139?

This trial is currently completed. It is a NA study. The enrollment target is 85 participants. The study started on 2020-10-06. Estimated completion is 2022-02-07.

What conditions does trial NCT04585139 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT04585139?

The interventions under investigation include: Phase 1- Introduction to Dexcom G6 CGM (DEVICE).

Who is sponsoring clinical trial NCT04585139?

This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04585139 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.